Comparative Pharmacology
Head-to-head clinical analysis: PHISOHEX versus READYPREP CHG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHISOHEX versus READYPREP CHG.
PHISOHEX vs READYPREP CHG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Disrupts bacterial cell wall synthesis by binding to the bacterial ribosome and inhibiting protein synthesis; also has surfactant properties that disrupt bacterial cell membrane integrity.
Chlorhexidine gluconate disrupts microbial cell membranes, causing leakage of cytoplasmic contents and cell death. Its cationic nature binds to negatively charged bacterial cell walls, providing persistent antimicrobial activity.
Apply topically as a 3% emulsion to affected area, rinse thoroughly; typically used 1-2 times daily for up to 10 days.
No standard systemic dosing; used as a 4% chlorhexidine gluconate topical antiseptic solution applied once daily to entire body for preoperative skin preparation or for chlorhexidine bathing in infection prevention protocols.
None Documented
None Documented
Terminal elimination half-life approximately 6-7 hours in adults with normal renal function. Prolonged in renal impairment (up to 20 hours) due to reduced clearance of active metabolite (pentachlorophenol).
60 minutes (terminal) in patients with normal renal function; prolonged in renal impairment.
Renal (biliary/fecal negligible). Up to 10% of dose excreted unchanged in urine; remainder as metabolites (glucuronide and sulfate conjugates).
Renal: ~100% unchanged via glomerular filtration. No biliary or fecal elimination.
Category C
Category C
Antiseptic
Antiseptic